Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.73+0.02 (+0.05%)
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Roivant Sciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$816.47M. For fiscal 2025 it was -$750.35M. The highest annual figure on record is -$552.14M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | -$750.35M | – |
| FY2024 | Mar 31, 2025 | -$839.45M | – |
| FY2023 | Mar 31, 2024 | -$765.27M | – |
| FY2022 | Mar 31, 2023 | -$843.39M | – |
| FY2021 | Mar 31, 2022 | -$677.73M | – |
| FY2020 | Mar 31, 2021 | -$552.14M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | -$270.50M | – |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | -$163.82M | – |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | -$196.48M | – |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | -$185.66M | – |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | -$204.38M | – |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | -$172.57M | – |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | -$207.25M | – |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | -$266.81M | – |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | -$192.83M | – |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | -$108.46M | – |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | -$210.45M | – |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | -$196.43M | – |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | -$249.93M | – |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | -$179.09M | – |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | -$222.59M | – |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | -$189.63M | – |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | -$252.08M | – |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | -$147.47M | – |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | -$268.49M | – |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | -$120.60M | – |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | -$141.17M | – |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | -$106.07M | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | -$236.86M | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | -$98.05M | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | -$111.17M | – |
See a number that looks wrong?